SARAH SCANTAMBURLO: Open Payments
NPI 1225348568 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$18,889 in 66 payments from 8 companies in 2025. Trend: 2023 $871 · 2024 $9,444 · 2025 $18,889
Speaker / faculty: $8,352Consulting: $6,480Food & beverage: $2,351Travel & lodging: $1,605Education: $101
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 37 | $17,525 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $403 |
| Teva Pharmaceuticals USA, Inc. | 4 | $243 |
| Neurocrine BioSciences, Inc. | 3 | $238 |
| Otsuka America Pharmaceutical, Inc. | 4 | $196 |
| Janssen Pharmaceuticals, Inc | 1 | $150 |
| Lundbeck LLC | 4 | $84 |
| Alkermes, Inc. | 2 | $51 |
Products named: COBENFY, CAPLYTA, INGREZZA, SPRAVATO, ABILIFY MAINTENA, UZEDY, REXULTI, ARISTADA.
Industry payments across MI — which companies pay providers there.
